The long await phase two clinical trial into Allergy Therapeutics’ (AGY) novel grass allergy vaccine has been successful. The trial managed to discover the appropriate dosage of the drug after a similar trial in 2015 failed to achieve any clinical significance. This latest update means Allergy can progress to its phase three study safe in the knowledge that patients are being given the appropriate dose.
If the rest of Allergy’s product development goes according to plan, 2018 should be the last year that losses widen, according to Panmure Gordon. The grass vaccine, in particular, could be an enormous commercial success if it manages to pass its final trial thanks to the size of the allergy market, which is largely devoid of long-term treatments.
